China FDA Set To Greenlight First Domestic Lymphoma Drug
This article was originally published in PharmAsia News
Executive Summary
On the verge of obtaining its first new drug approval from the China FDA to treat a rare cancer type, Chinese domestic biotech ChipScreen is poised to benefit from an increasingly confident regulatory agency.